Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Araujo, John C, Trudel, Geralyn C, Paliwal, Prashni
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2013
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601649/
https://ncbi.nlm.nih.gov/pubmed/23516140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S41667
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak